Alpha-GPC

The trials in healthy people are few and small, most lasted a week or less, and several were funded by companies that sell alpha-GPC. Our evidence grading method explains what each grade requires. Each grade below covers short-term use only.

Does alpha-GPC improve power output and strength?

Evidence is mixed, and the trials are small. In a double-blind, placebo-controlled crossover trial funded by the ingredient supplier Chemi Nutra, 13 college-aged men took 600 mg of alpha-GPC a day or placebo for 6 days [3]. Peak force on the isometric mid-thigh pull (a maximal pull measured on a force platform) rose more with alpha-GPC than with placebo (p = 0.044) [3]. In the same Chemi Nutra-funded trial, an upper-body isometric test trended the same way but did not reach statistical significance (p = 0.127) [3].

A larger trial from the same research group, also funded by Chemi Nutra, randomly assigned 48 healthy college-aged men to 500 mg of alpha-GPC, 250 mg of alpha-GPC, 200 mg of caffeine or placebo daily for 7 days [2]. This supplier-funded trial found group differences in maximum velocity and maximum mechanical power on the countermovement jump, with the 250 mg group showing the greatest improvement [2]. The same Chemi Nutra-funded trial found no differences between groups on the isometric mid-thigh pull or the upper-body isometric test [2]. The paper states that no Chemi Nutra employee had a role in its design, interpretation or writing [2].

A third trial points the other way. In a randomized, double-blind, placebo-controlled crossover trial funded by the ingredient supplier NNB Nutrition, 20 resistance-trained men took a single dose of 315 mg or 630 mg of alpha-GPC or placebo before vertical jumps, bench press throws and a squat workout [1]. That supplier-funded trial found no group differences in physical performance or growth hormone [1]. Its author is a paid scientific advisor to the sponsor, and the trial was registered only after it ran [1].

One other trial is often quoted but cannot isolate alpha-GPC. In 30 trained male cyclists with an average age of 43.7, a combination of 8 g of branched-chain amino acids, 6 g of L-citrulline and 300 mg of alpha-GPC taken for 7 days increased peak power in a 20 km time trial compared with placebo, but not completion time or average power [4]. Because the product had three active ingredients, the result cannot be credited to alpha-GPC [4].

Growth hormone results are sometimes cited. In a double-blind crossover study of 8 healthy young men, a single 1,000 mg dose of alpha-GPC raised growth hormone 60 minutes later, while placebo did not [6]. A rise in a hormone is a biomarker, not a performance outcome, and the supplier-funded trial of 20 men found no group difference in growth hormone after exercise [1][6].

Does alpha-GPC improve attention?

One small trial found a benefit on one test of three. In the NNB Nutrition-funded crossover trial of 20 resistance-trained men, Stroop total score improved more after 630 mg (d = 0.61) and 315 mg (d = 0.48) of alpha-GPC than after placebo, measured 60 minutes after the dose [1]. In that supplier-funded trial, the 630 mg dose also shortened the time to complete the Stroop test compared with placebo [1]. The same trial found no significant differences on the Flanker and N-Back tests, with only a tendency toward faster Flanker reaction times at the higher dose [1].

The 7-day Chemi Nutra-funded trial of 48 healthy college-aged men found no differences between groups on the psychomotor vigilance task, a standard test of sustained attention and reaction time [2]. Taken together, these two supplier-funded trials in young men do not show a consistent effect on attention [1][2].

Does alpha-GPC affect motivation?

One publicly funded trial measured how people felt. In a single-blind, placebo-controlled trial, 39 healthy volunteers rated their feelings three times a day for two weeks before and two weeks during treatment [5]. Alpha-GPC showed a tendency to raise self-rated motivation over the treatment period, and night-time motivation was significantly higher than with placebo, with no effect on anxiety ratings [5]. The study was single-blind and relied on self-reported feelings, which limits confidence [5].

What the evidence does not show

As of November 11, 2026 we found no meta-analysis of alpha-GPC trials in healthy adults (PubMed search, November 11, 2026). The meta-analyses we found were in clinical populations. One systematic review and meta-analysis of 7 randomized controlled trials and 1 prospective cohort study pooled adults with cognitive impairment from neurological conditions linked to blood vessel injury, a clinical population, and reported better cognition with alpha-GPC alone or added to a prescription medicine [15]. Results may not apply to healthy adults [15].

The power and attention trials, funded by the ingredient suppliers NNB Nutrition and Chemi Nutra, were short, from a single dose to 7 days of use, and enrolled men only [1][2][3]. These supplier-funded trials do not show what happens with longer use or in women [1][2][3].

Alpha-GPC is rapidly absorbed and acts as a source of choline [13]. In 8 healthy young men, plasma free choline rose at 60 and 120 minutes after a single 1,000 mg dose [6]. In a crossover study of six healthy men co-funded by the food manufacturer HiPP, a single dose of alpha-GPC raised blood choline about as much as choline chloride, choline bitartrate or egg phosphatidylcholine, judged by the area under the concentration curve [7]. A 2026 review notes that how alpha-GPC is absorbed and broken down in the gut is still unclear [12].

Timing in trials was a study design choice, not a finding about the best time: the NNB Nutrition-funded single-dose trial tested people 60 minutes after the dose [1], and the Chemi Nutra-funded strength trials gave alpha-GPC daily for 6 or 7 days [2][3]. Forms used include a branded alpha-GPC ingredient in the NNB Nutrition-funded trial [1] and liquid and powder forms made from soy lecithin in the product EFSA assessed [13].

A 2025 review reports no severe adverse effects of alpha-GPC in human studies, and says that possible risks of atherosclerosis and stroke still await validation [11]. Health Canada's safety assessment found no toxicological concern in animal data and human clinical studies [19]. It also notes there were no human data above 1,200 mg a day, and none at any dose in pregnant or breastfeeding women, children or adolescents [19].

The NIH Office of Dietary Supplements' choline fact sheet covers choline in general, not alpha-GPC specifically. It states that high intakes of choline are associated with a fishy body odor, vomiting, excessive sweating and salivation, low blood pressure (hypotension) and liver toxicity [21]. Its upper intake levels for choline from food and supplements are based on the amounts linked to low blood pressure and fishy body odor, and they do not apply to people taking high doses of choline under medical supervision [21].

Trial findings on side effects are sparse. In the Chemi Nutra-funded 7-day trial, serum thyroid stimulating hormone (TSH) was significantly lower in the 500 mg group than in the other groups [2]. In the NNB Nutrition-funded single-dose trial, heart rate and blood pressure changed in all groups, including placebo, and stayed within normal values [1].

Animal studies give a sense of acute toxicity. In rats and mice the oral LD50 (the dose that kills half the animals) was 10,000 mg/kg or more, and some deaths were preceded by convulsions [14]. The same safety assessment found alpha-GPC was not genotoxic and set a no-observed-adverse-effect level of 150 mg/kg body weight a day after 26 weeks [14]. EFSA noted several limitations in the animal safety data submitted by the applicant, but concluded the product does not raise safety concerns at its proposed use [13].

What is the TMAO question?

TMAO (trimethylamine N-oxide) is made when gut bacteria break down choline, and choline has been linked to higher cardiovascular risk through TMAO [9]. A 2026 narrative review describes the evidence linking high intake of choline compounds, including alpha-GPC, to TMAO and atherosclerosis, and concludes that the harm from TMAO remains debatable [12]. This page reports that discussion; it does not give advice on it.

Human studies of alpha-GPC and TMAO are small and disagree. In a randomized crossover study of six healthy men, co-funded by the food manufacturer HiPP, all water-soluble choline supplements, alpha-GPC among them, rapidly increased TMAO, whereas egg phosphatidylcholine did not [7]. In a randomized trial of 12 healthy men funded by Otsuka Pharmaceutical, glycerophosphocholine raised plasma choline but did not significantly raise TMAO [8].

In mice bred to develop high blood fats, alpha-GPC promoted atherosclerosis, and the authors proposed TMAO as one mechanism [10]. This is an animal study funded by the NIH, ZonMw and the Leducq Foundation [10]. Two of its authors are named inventors on patents related to cardiovascular diagnostics and therapeutics and have received royalties from Cleveland Heart Lab and Procter & Gamble; separately from this study, one is a paid consultant for Procter & Gamble and Zehna Therapeutics and has received research funds from those companies, Pfizer and Roche Diagnostics [10].

The strongest human signal comes from an observational study. A retrospective cohort study used South Korean national health insurance data on 12,008,977 adults aged 50 or older without previous stroke [9]. After matching, people prescribed alpha-GPC had a higher risk of total stroke than non-users (aHR 1.43; 95% CI, 1.41-1.46), and greater use was associated with higher risk in a dose-response pattern [9]. The paper was later corrected because two stroke codes were swapped in its Methods; the correction did not change the reported results [9]. A cohort study shows an association, not cause, and its participants were older adults prescribed the compound, so results may not apply to younger healthy adults [9]. The health conditions or symptoms that led people to receive alpha-GPC could also contribute to the association [9]. The authors call for further studies of possible mechanisms [9].

As of November 11, 2026 we found no human drug-interaction studies of alpha-GPC (PubMed and Europe PMC search, November 11, 2026). The NIH Office of Dietary Supplements' choline fact sheet states that choline is not known to have any clinically relevant interactions with medications; the statement is about choline in general, not alpha-GPC specifically [21]. For choline in supplemented foods, Health Canada's cautionary labeling for products above a set choline amount per serving includes a statement not to consume the product on the same day as any other supplemented foods or supplements with choline, naming alpha-GPC among them [18].

These sources describe what has been reported, not what is right for any individual. If you take any prescription medicines, talk to your doctor or pharmacist before combining them with alpha-GPC.